A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 11, 2012, Pages 1703-1706

  Grant Klein, Rebecca J ^a   Van Deusen, Nicole M ^a   Badger, Catherine V ^a   Hannaman, Drew ^b   Dupuy, Lesley C ^a   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Ichor Medical Systems Inc   (United States)

Author keywords

Codon optimized; DNA vaccine; Ebola virus; Electroporation; Filovirus; Marburg virus; Mice

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CODON; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTRODE; ELECTROPORATION; ELECTROSTIMULATION; FEMALE; FILOVIRUS; IMMUNOGENICITY; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MOUSE; NONHUMAN; SURVIVAL RATE; TIBIALIS ANTERIOR MUSCLE;

CODON-OPTIMIZED; DNA VACCINE; EBOLA VIRUS; ELECTROPORATION; FILOVIRUS; MARBURG VIRUS; MICE;

ANIMALS; EBOLAVIRUS; ELECTROPORATION; FEMALE; HEMORRHAGIC FEVER, EBOLA; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED BALB C; MUSCLES; VACCINES, DNA;

EID: 84868146325     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21873     Document Type: Article

References (13)

1. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103; PMID:21046175; http://dx.doi.org/10.1007/s00705-010-0814-x.
2. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80; PMID:12922144; http://dx.doi.org/10.1016/S0264-410X(03)00362- 1.
3. Cid-Arregui A, Juárez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 2003; 77:4928-37; PMID:12663798; http://dx.doi.org/10.1128/JVI.77.8.4928-4937.2003.
4. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, et al. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18:707-16; PMID:21450977; http://dx.doi.org/10.1128/ CVI.00030-11.
5. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-88; PMID:18781156; http://dx.doi.org/10.1038/nrg2432.
6. Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 2007; 25:7271-9; PMID:17825960; http://dx.doi.org/10.1016/j. vaccine.2007.07.025.
7. Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001; 75:10991-1001; PMID:11602739; http://dx.doi.org/10.1128/ JVI.75.22.10991-11001.2001.
8. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 2010; 84:10386-94; PMID:20660192; http://dx.doi.org/10.1128/JVI.00594-10.
9. Luxembourg A, Hannaman D, Wills K, Bernard R, Tennant BC, Menne S, et al. Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine 2008; 26:4025-33; PMID:18556096; http://dx.doi.org/10.1016/j.vaccine.2008.05.021.
10. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61; PMID:9728532; http://dx.doi.org/10.1086/515386.
11. Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83:6404-15; PMID:19369350; http://dx.doi.org/10.1128/JVI.00126- 09.
12. Badger CV, Richardson JD, Dasilva RL, Richards MJ, Josleyn MD, Dupuy LC, et al. Development and application of a flow cytometric potency assay for DNA vaccines. Vaccine 2011; 29:6728-35; PMID:21219978; http://dx.doi.org/10.1016/j. vaccine.2010.12.053.
13. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6; PMID:10698744; http://dx.doi.org/10.1126/science.287.5458. 1664.